Based on 1 analysts giving stock ratings to Xilio Therapeutics Inc in the past month.
In the current month, XLO has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. XLO average Analyst price target in the last month is 20.000.
Based on analysts' estimates, XLO EPS is projected to reach -0.850 in FY2026Q4, following reported EPS of -0.302 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
The market expectation was USD -0.30, while Xilio Therapeutics IncXLO's earnings per share (EPS) for the previous quarter was USD -0.33. EPS for the next quarter is expected at USD -0.85.